Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Eli Lilly Achieves 80% Jump In COVID-19 Therapy Sales, Revises FY22 Guidance

Eli Lilly And Co (NYSE:LLY) has posted Q1 sales of $7.8 billion, beating the consensus of $6.68 billion. Lilly's revenue increased 15%, driven by volume growth of 20%, partially offset by a 3% decrease due to lower realized prices and a 2% decrease due to the unfavorable impact of foreign exchange rates. …

Benzinga

Peering Into Eli Lilly and Company's Recent Short Interest

Eli Lilly and Company's (NYSE:LLY) short percent of float has fallen 12.05% since its last report. The company recently reported that it has 5.79 million shares sold short, which is 0.73% of all regular shares that are available for trading.

Benzinga

Eli Lilly: Q1 Earnings Insights

Eli Lilly (NYSE:LLY) reported its Q1 earnings results on Thursday, April 28, 2022 at 06:25 AM. Here's what investors need to know about the announcement.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Earnings Preview For Eli Lilly

Eli Lilly (NYSE:LLY) is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Here's what investors need to know before the announcement. Analysts estimate that Eli Lilly will report an earnings per share (EPS) of $2.13.

Benzinga

How To Attend Eli Lilly Q1 2022 Earnings Conference Call

Eli Lilly (NYSE:LLY) will host a conference call at 09:00 AM ET on April 28, 2022, to discuss Q1 2022 earnings results. How to Attend Eli Lilly (LLY) Conference Call Follow this link to access the live webcast.

Benzinga

Executives Sell Over $44M Of 4 Stocks

Although gold futures traded slightly lower on Friday, there were a few notable insider trades.

Benzinga

Eli Lilly Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 37 strange trades.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Where Eli Lilly Stands With Analysts

Over the past 3 months, 5 analysts have published their opinion on Eli Lilly (NYSE:LLY) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

US pulls GSK's COVID drug as omicron sibling dominates cases

U.S. regulators say GlaxoSmithKline’s COVID-19 antibody drug should no longer be used because it is likely ineffective against the latest version of the virus that accounts for most cases

The Independent UK

Alphabet And 2 Other Stocks Insiders Are Selling

Although the Nasdaq Composite dropped around 2% on Tuesday, there were a few notable insider trades.

Benzinga

Peering Into Eli Lilly and Company's Recent Short Interest

Eli Lilly and Company's (NYSE:LLY) short percent of float has risen 22.39% since its last report. The company recently reported that it has 6.50 million shares sold short, which is 0.82% of all regular shares that are available for trading.

Benzinga

If You Invested $100 In Eli Lilly 10 Years Ago, Here's How Much You Would Have Today

Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 9.2% on an annualized basis producing an average annual return of 21.76%. Currently, Eli Lilly has a market capitalization of $274.87 billion.

Benzinga

Will AI turbocharge the hunt for new drugs?

Advocates point to the pandemic as proof of its value in healthcare even as critics dismiss its use in drug discovery as ‘hype’

Financial Times

Looking Into Eli Lilly and Company's Recent Short Interest

Eli Lilly and Company's (NYSE:LLY) short percent of float has risen 13.56% since its last report. The company recently reported that it has 5.36 million shares sold short, which is 0.67% of all regular shares that are available for trading.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Check Out What Whales Are Doing With LLY

Someone with a lot of money to spend has taken a bearish stance on Eli Lilly (NYSE:LLY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Eli Lilly's Phase 3 Jardiance Study Stopped Early Due To Clear Positive Efficacy In Kidney Disease

Based on the Independent Data Monitoring Committee's recommendation, Boehringer Ingelheim and Eli Lilly And Co (NYSE: LLY) will stop early its EMPA-KIDNEY trial of Jardiance (empagliflozin) in adults with chronic kidney disease (CKD).

Benzinga

Here's How Much $100 Invested In Eli Lilly 5 Years Ago Would Be Worth Today

Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 13.68% on an annualized basis.

Benzinga

Eli Lilly's JAK Inhibitor Baricitinib Cuts Death Risk By 13% In COVID-19 Patients

According to a British study, Eli Lilly And Co (NYSE:LLY) and Incyte Corporation's (NASDAQ:INCY) Olumiant (baricitinib) reduced the risk of death in hospitalized COVID-19 patients by 13%. According to a Reuters report, more than 8,000 patients were administered baricitinib in addition to standard of care in the RECOVERY Trial. Results showed that 546 patients…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Eli Lilly And 3 Other Stocks Sold By Insiders

Although US crude oil futures traded higher this morning, there were a few notable insider trades.

Benzinga

FDA Approves Eli Lilly's Jardiance In Broader Heart Patient Population

The FDA approved Eli Lilly And Co (NYSE:LLY) and partner Boehringer Ingelheim's drug, Jardiance, for expanded use in reducing the risk of death and hospitalization for all patients with heart failure. Initially approved by the FDA in 2014 for type 2 diabetes patients, the drug's use was expanded last year in some adults living with heart failure…

Benzinga

Nearly 66% Of Patients Respond To Eli Lilly's Mirikizumab In Ulcerative Colitis Study

Patients with moderately-to-severely active ulcerative colitis (UC) who took Eli Lilly And Co's (NYSE: LLY) mirikizumab

Benzinga

ICER's Report Suggests Benefits Of Eli Lilly's Tirzepatide Not Better Than Other Diabetes Drugs

Institute for Clinical and Economic Review (ICER) casts doubts on Eli Lilly And Co’s (NYSE: LLY) tirzepatide, a type II diabetes candidate, about its usefulness to patients compared to the rivals.

Asharq Al-Awsat

US FDA Advisers Say More Data Needed for Cancer Drug Tested in China

A panel of outside advisers to the US Food and Drug Administration on Thursday voted to recommend that Innovent Biologics Inc and Eli Lilly and Co be required to conduct a trial of their lung cancer drug that is applicable to the US population. Data submitted to the FDA for…

Benzinga

Eli Lilly Q4 Earnings Beat Estimates On Higher Demand For Trulicity, COVID-19 Therapies; Reaffirms FY22 Guidance

Eli Lilly And Co (NYSE: LLY) has

Benzinga

Eli Lilly: Q4 Earnings Insights

Eli Lilly (NYSE:LLY) reported its Q4 earnings results on Thursday, February 3, 2022 at 06:25 AM. Here's what investors need to know about the announcement.

1 … 25 26 27 28

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

US Food and Drug Administration

62 stories

Eli Lilly and Company

57 stories

Eli Lilly And Co

54 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.